April 2026 in “Therapeutic Advances in Drug Safety” This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.
39 citations
,
October 2015 in “Case Reports” In this case series, four adults developed severe, disabling multisymptom illness potentially linked to fluoroquinolone use, which persisted and progressed even after discontinuation of the drug.
September 2021 in “Journal of skin and stem cell” Lactium, a milk protein, can help reduce symptoms of skin disorders linked to stress and anxiety without side effects.
May 2026 in “AAPS PharmSciTech” This study found that PEGylated LUT-Aspasomes significantly improved neuroprotective effects in stressed rats, enhancing spatial memory, reducing depressive-like behavior, and preserving hippocampal architecture better than free luteolin. Additionally, it increased brain delivery and stability, suggesting potential for treating stress-related neurobehavioral disorders.
April 2026 in “Frontiers in Pharmacology” This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.
